<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538745</url>
  </required_header>
  <id_info>
    <org_study_id>C.2011.173</org_study_id>
    <nct_id>NCT01538745</nct_id>
  </id_info>
  <brief_title>Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department</brief_title>
  <official_title>Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Air Force Office of the Surgeon General</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of intravenous low dose&#xD;
      ketamine (LDK) to the industry standard of morphine (MOR) in regards to controlling acute&#xD;
      pain in the emergency department.&#xD;
&#xD;
      Both LDK and morphine have side effects. The amount and character of these side effects will&#xD;
      be compared. Additionally, the degree of sedation or agitation will be specifically measured.&#xD;
      The aim of this current study is to make this comparison and shift the evidence for LDK use&#xD;
      from the anecdotal to the scientific.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 is a randomized, controlled, double-blinded study comparing the use of low-dose&#xD;
      ketamine (LDK) to morphine for acute pain control in emergency department patients. A&#xD;
      convenience sample of subjects will be enrolled from a population of patients aged 18-50 who&#xD;
      present to the Brooke Army Medical Center Emergency Department with acute abdominal pain,&#xD;
      flank/lumbar back pain and/or pain to the extremities. To take part in the study, a need for&#xD;
      opioid analgesia must be indicated by the treating physician in addition to the patient&#xD;
      meeting all other study criteria.&#xD;
&#xD;
      The patient will then be randomized into one of the two treatment arms. Prior to receiving&#xD;
      either the study medication (ketamine) or the active control (morphine) the patient will be&#xD;
      asked to rate their pain on a numeric rating scale (NRS) with 0 being no pain and 10 being&#xD;
      the worst pain possible. Their baseline vital signs (blood pressure, heart rate, respiratory&#xD;
      rate and oxygen saturation) will also be documented. These vital signs and the NRS will be&#xD;
      reassessed at 5, 10 and 20 minutes post medication dosage. At 20 minutes they will also&#xD;
      document a Richmond Agitation Sedation Scale (RASS) score and will ask the patient if they&#xD;
      require additional pain medication. If the patient denies the need for a second dose of&#xD;
      medication they will continue to be re-assessed every 20 minutes (vital signs, NRS, and RASS)&#xD;
      until either inpatient admission, discharge home, transfer to the operating room or until a&#xD;
      total of 120 minutes after initial dosing.&#xD;
&#xD;
      If at any time during the study the patient requires a second dose of pain medication,&#xD;
      following the administration of the med, they will be assessed for vital signs at 5,10 and 20&#xD;
      minutes after the dose. At 20 minutes, a RASS score and NRS score will also be documented.&#xD;
      They will then be re-assessed every 20 minutes (vital signs, NRS, and RASS) until either&#xD;
      inpatient admission, discharge home, transfer to the operating room or until a total of 120&#xD;
      minutes after initial dosing.&#xD;
&#xD;
      If they require a third dose of pain medication at any time during the study, this is&#xD;
      considered a treatment failure and the treating physician will be contacted to provide any&#xD;
      further pain control.&#xD;
&#xD;
      The second phase of the study will be observational. An anonymous satisfaction survey will be&#xD;
      provided to the treating nurse, physician or physicians assistant (PA) of the patients&#xD;
      recruited from part one of the study. The purpose of conducting the survey is so that an&#xD;
      observation point of view can be added to the data to provide a measure of how well the&#xD;
      patient's pain was controlled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Change in Numerical Rating Scale (NRS) Pain Score From Baseline NRS Pain Score</measure>
    <time_frame>5,10,20,40,60,80,100,120 minutes post dose</time_frame>
    <description>Numerical Rating Scale (NRS) pain score is an 11-point rating scale for pain. With 0 being no pain and 10 being the worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Change in NRS Pain Score</measure>
    <time_frame>5,10, 20,40,60,80,100,120 minutes</time_frame>
    <description>Following dosage with study medication, the amount of time taken to demonstrate a change in the patient's NRS pain score. Time to Change in NRS Pain Score for the Reporting Group as a whole will be made</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximal Change in NRS Pain Score</measure>
    <time_frame>5, 10, 20 minutes and then every 20 minutes to a total of 120 minutes</time_frame>
    <description>Following dosage with study medication, the interval time taken to demonstrate the maximal change in the patient's NRS pain score will be reported for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Failure</measure>
    <time_frame>120 minutes</time_frame>
    <description>Requiring more than two doses of the study medication provided for adequate pain control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Side Effects, Including Outlying Vital Signs</measure>
    <time_frame>5,10,20,40,60,80,100,120 minutes</time_frame>
    <description>The patient will be assessed for vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation), and all side effects at 5,10,20 minutes following medication administration and then every 20 minutes until a total of 120 minutes from the first dose of study medication. All side effects and outlying vital signs will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Deviation From 0 on the Richmond Agitation Sedation Scale (RASS)</measure>
    <time_frame>5,10,20,40,60,80,100,120 minutes</time_frame>
    <description>Using 0 as the &quot;normal/baseline&quot; on the RASS, maximal deviation in either direction will be used to demonstrate the effect of the study medications on levels of sedation or agitation. Results will be reported as&#xD;
Richmond Agitation Sedation Scale (RASS) scores range from:&#xD;
4 Combative: Overtly combative, violent, immediate danger to staff&#xD;
3 Very agitated: Pulls or removes tube(s) or catheter(s); aggressive&#xD;
2 Agitated: Frequent non-purposeful movement&#xD;
1 Restless: Anxious but movements not aggressive. vigorous 0 Alert and calm&#xD;
1 Drowsy: Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (&gt;10 seconds)&#xD;
2 Light sedation: Briefly awakens with eye contact to voice (&lt;10 seconds)&#xD;
3 Moderate sedation: Movement or eye opening to voice (but no eye contact)&#xD;
4 Deep sedation: No response to voice, but movement or eye opening to physical stimulation&#xD;
5 Unarousable: No response to voice or physical stimulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Abdomen, Acute</condition>
  <condition>Other Acute Pain</condition>
  <condition>Flank Pain</condition>
  <condition>Back Pain</condition>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>MS Contin</other_name>
    <other_name>Roxanol</other_name>
    <other_name>Kadian</other_name>
    <other_name>Avinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age 18-59 who present to the Brooke Army Medical Center Emergency Department&#xD;
             with acute (less than 10 days) abdominal pain, flank/lumbar back pain and or/pain to&#xD;
             the extremities, and of sufficient severity in the judgement of the ED treating&#xD;
             physician or PA to warrant use of intravenous opioids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor vital sign stability hypoxia: Sats&lt;95% hypotension: SBP&lt;90 hypertension: SBP&gt;180&#xD;
             heart rate: &lt;50 or &gt;120 respiratory rate: &lt;10 or &gt;30&#xD;
&#xD;
          -  Altered mental status or intoxication&#xD;
&#xD;
          -  Patient is unwilling to participate or provide informed consent&#xD;
&#xD;
          -  History of chronic pain or pain syndrome with concurrent opioid medication use&#xD;
&#xD;
          -  fibromyalgia&#xD;
&#xD;
          -  Patient has received opioids and/or tramadol in the past 4 hours&#xD;
&#xD;
          -  Prescription pain medication use (to exclude muscle relaxants, acetaminophen or NSAIDs&#xD;
             including toradol) in the past 4 hours&#xD;
&#xD;
          -  Allergy to morphine or ketamine&#xD;
&#xD;
          -  Sole provider status&#xD;
&#xD;
          -  Adverse reaction to morphine or ketamine in the past&#xD;
&#xD;
          -  Patients, who in the opinion of the triage nurse, require immediate analgesic relief&#xD;
&#xD;
          -  Patient is female of child-bearing age and unable to provide urine or serum for HCG&#xD;
             analysis in triage&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Presence of oxygen dependent pulmonary disease, liver cirrhosis or Renal disease&#xD;
             requiring dialysis. (as assessed by electronic chart review)&#xD;
&#xD;
          -  Presence of Ischemic heart disease, heart failure or unstable dysrhythmias (as&#xD;
             assessed by electronic chart review)&#xD;
&#xD;
          -  Presence of intracranial mass or vascular lesion.&#xD;
&#xD;
          -  Presence of psychosis or hallucinations&#xD;
&#xD;
          -  Weight greater than 115kg or less than 45 kg&#xD;
&#xD;
          -  History of acute ocular/head trauma&#xD;
&#xD;
          -  History of increased intracranial pressure/hypertensive hydrocephalus&#xD;
&#xD;
          -  Non-English speaking patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua P Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Air Force</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <results_first_submitted>July 17, 2013</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Joshua Miller</investigator_full_name>
    <investigator_title>Joshua Miller, Maj, USAF, MC</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Emergency Department</keyword>
  <keyword>Morphine</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Flank Pain</mesh_term>
    <mesh_term>Abdomen, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study took place at a Level 1 trauma center. The patient population at SAMMC consists of active duty military personnel and their family members, retirees, as well as civilians. There are approximately 75,000 visits to the SAMMC ED annually. Enrollment occurred from February 2012 to March 2013.</recruitment_details>
      <pre_assignment_details>Patients were excluded if: O2 saturation &lt;95%, SBP &lt; 90mmHg or &gt; 180mmHg, HR&lt; 50 or &gt; 120 beats per minute, RR &lt; 10 or &gt; 30 per minute, altered mental status, intoxication, history fibromyalgia, ischemic heart disease, heart failure or unstable dysrhythmias, required pain medication immediately and cannot wait to consent</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
        </group>
        <group group_id="P2">
          <title>Morphine</title>
          <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
        </group>
        <group group_id="B2">
          <title>Morphine</title>
          <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.75" spread="11.87"/>
                    <measurement group_id="B2" value="29.29" spread="9.78"/>
                    <measurement group_id="B3" value="30.07" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Change in Numerical Rating Scale (NRS) Pain Score From Baseline NRS Pain Score</title>
        <description>Numerical Rating Scale (NRS) pain score is an 11-point rating scale for pain. With 0 being no pain and 10 being the worst pain imaginable.</description>
        <time_frame>5,10,20,40,60,80,100,120 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Change in Numerical Rating Scale (NRS) Pain Score From Baseline NRS Pain Score</title>
          <description>Numerical Rating Scale (NRS) pain score is an 11-point rating scale for pain. With 0 being no pain and 10 being the worst pain imaginable.</description>
          <units>NRS pain scale score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>units on a scale</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>units on a scale</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" lower_limit="-5.75" upper_limit="-4"/>
                    <measurement group_id="O2" value="-5" lower_limit="-7.1" upper_limit="-2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Change in NRS Pain Score</title>
        <description>Following dosage with study medication, the amount of time taken to demonstrate a change in the patient's NRS pain score. Time to Change in NRS Pain Score for the Reporting Group as a whole will be made</description>
        <time_frame>5,10, 20,40,60,80,100,120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Change in NRS Pain Score</title>
          <description>Following dosage with study medication, the amount of time taken to demonstrate a change in the patient's NRS pain score. Time to Change in NRS Pain Score for the Reporting Group as a whole will be made</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="2.63"/>
                    <measurement group_id="O2" value="5" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximal Change in NRS Pain Score</title>
        <description>Following dosage with study medication, the interval time taken to demonstrate the maximal change in the patient's NRS pain score will be reported for each group.</description>
        <time_frame>5, 10, 20 minutes and then every 20 minutes to a total of 120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximal Change in NRS Pain Score</title>
          <description>Following dosage with study medication, the interval time taken to demonstrate the maximal change in the patient's NRS pain score will be reported for each group.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.7"/>
                    <measurement group_id="O2" value="120" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment Failure</title>
        <description>Requiring more than two doses of the study medication provided for adequate pain control</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment Failure</title>
          <description>Requiring more than two doses of the study medication provided for adequate pain control</description>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Side Effects, Including Outlying Vital Signs</title>
        <description>The patient will be assessed for vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation), and all side effects at 5,10,20 minutes following medication administration and then every 20 minutes until a total of 120 minutes from the first dose of study medication. All side effects and outlying vital signs will be documented.</description>
        <time_frame>5,10,20,40,60,80,100,120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Side Effects, Including Outlying Vital Signs</title>
          <description>The patient will be assessed for vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation), and all side effects at 5,10,20 minutes following medication administration and then every 20 minutes until a total of 120 minutes from the first dose of study medication. All side effects and outlying vital signs will be documented.</description>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Deviation From 0 on the Richmond Agitation Sedation Scale (RASS)</title>
        <description>Using 0 as the &quot;normal/baseline&quot; on the RASS, maximal deviation in either direction will be used to demonstrate the effect of the study medications on levels of sedation or agitation. Results will be reported as&#xD;
Richmond Agitation Sedation Scale (RASS) scores range from:&#xD;
4 Combative: Overtly combative, violent, immediate danger to staff&#xD;
3 Very agitated: Pulls or removes tube(s) or catheter(s); aggressive&#xD;
2 Agitated: Frequent non-purposeful movement&#xD;
1 Restless: Anxious but movements not aggressive. vigorous 0 Alert and calm&#xD;
1 Drowsy: Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (&gt;10 seconds)&#xD;
2 Light sedation: Briefly awakens with eye contact to voice (&lt;10 seconds)&#xD;
3 Moderate sedation: Movement or eye opening to voice (but no eye contact)&#xD;
4 Deep sedation: No response to voice, but movement or eye opening to physical stimulation&#xD;
5 Unarousable: No response to voice or physical stimulation</description>
        <time_frame>5,10,20,40,60,80,100,120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
          <group group_id="O2">
            <title>Morphine</title>
            <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Deviation From 0 on the Richmond Agitation Sedation Scale (RASS)</title>
          <description>Using 0 as the &quot;normal/baseline&quot; on the RASS, maximal deviation in either direction will be used to demonstrate the effect of the study medications on levels of sedation or agitation. Results will be reported as&#xD;
Richmond Agitation Sedation Scale (RASS) scores range from:&#xD;
4 Combative: Overtly combative, violent, immediate danger to staff&#xD;
3 Very agitated: Pulls or removes tube(s) or catheter(s); aggressive&#xD;
2 Agitated: Frequent non-purposeful movement&#xD;
1 Restless: Anxious but movements not aggressive. vigorous 0 Alert and calm&#xD;
1 Drowsy: Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (&gt;10 seconds)&#xD;
2 Light sedation: Briefly awakens with eye contact to voice (&lt;10 seconds)&#xD;
3 Moderate sedation: Movement or eye opening to voice (but no eye contact)&#xD;
4 Deep sedation: No response to voice, but movement or eye opening to physical stimulation&#xD;
5 Unarousable: No response to voice or physical stimulation</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-3" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="-2" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.&#xD;
Ketamine : 0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.</description>
        </group>
        <group group_id="E2">
          <title>Morphine</title>
          <description>0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.&#xD;
Morphine : 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The side effect profile associated with ketamine and morphine are different without significant overlap thus making blinding difficult.&#xD;
The exclusion criteria of our study made enrollment difficult and our sample size smaller than anticipated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Josh Miller</name_or_title>
      <organization>SAUSHEC</organization>
      <phone>210-916-7111</phone>
      <email>joshmillersr@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

